Author: [AUTHOR] Published on 2/10/2023 6:00:00 AM
FDA Office of Clinical Pharmacology Announces Availability of 2022 Annual Report
The US Food and Drug Administration (FDA), Office of Clinical Pharmacology (OCP) announces the availability of the
2022 OCP Annual Report. OCP is a dynamic, purpose-driven organization dedicated to promoting and protecting global public health through the application of clinical pharmacology and translational medicine principles.
The theme of this year’s report is “
Innovation,” demonstrated in every aspect of OCP’s work, including regulatory review, policy development and implementation, research, stakeholder engagement, and program management. This report spotlights the dedication of OCP staff to the mission of FDA and their collaborative efforts toward improving public health by combining state-of-the-art translational science with rigorous regulatory assessment.
The 2022 OCP Annual Report also highlights the Office’s strategic priorities and “
Roadmap to 2025”, a plan that will act as a guide in making values-driven decisions that ultimately accelerate the science of clinical pharmacology and translational medicine for the benefit of patients.
Learn more about OCP’s diverse functional responsibilities, dedicated and collaborative culture, achievements, and 2023 outlook in the
2022 OCP Annual Report. To access past OCP annual reports and learn more about OCP, visit the
OCP webpage.
The Office of Clinical Pharmacology (OCP) is pleased to offer the e-mail subscription service Clinical Pharmacology Corner. This is a free service from FDA to provide occasional updates from OCP regarding newly approved therapies, new regulatory and scholarly publications, upcoming events and other items of interest. Subscribe today at
https://public.govdelivery.com/accounts/USFDA/subscriber/topics and select Clinical Pharmacology Corner under Drugs.
We always welcome your thoughts regarding the format, content, and utility of this communication. Comments may be sent via email to
ocp@fda.hhs.gov.
This communication was prepared by Office of Clinical Pharmacology, Office of Translational Sciences, CDER, FDA.